Athanasios D Anastasilakis
424 General Military Hospital, Thessaloniki, Greece · 424 Gen. Military Hospital Thessaloniki, Greece · 424 General Military Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Athanasios D Anastasilakis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:45 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05493761 · Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver DiseaseAristotle University Of Thessaloniki · completed · Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal · study director
- N/ANCT04338529 · Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation251 Hellenic Air Force & VA General Hospital · completed · Postmenopausal Osteoporosis · study director
- Ph4NCT02499237 · Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation424 General Military Hospital · completed · Postmenopausal Osteoporosis · principal investigator
- N/ANCT02498431 · Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention424 General Military Hospital · completed · Myocardial Infarction, Coronary Artery Disease · principal investigator
- N/ANCT01986530 · Circulating Levels of Irisin in Healthy Young Subjects424 General Military Hospital · completed · Healthy Subjects · principal investigator
- N/ANCT01572545 · Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone MassAristotle University Of Thessaloniki · completed · Postmenopausal Osteoporosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:45 UTC. The ranking covers the 200 most relevant of 34 PubMed records, and a shared surname and initials can bring in a namesake. All 34 on PubMed
- Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.J Bone Miner Res · 2008219 citationsRCR 6.7
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.J Bone Miner Res · 2019135 citationsRCR 7.8
- The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.J Clin Endocrinol Metab · 202161 citationsRCR 4.8
- Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.Clin Endocrinol (Oxf) · 201356 citationsRCR 2.2
- Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.Osteoporos Int · 201556 citationsRCR 2.4
- 52 citationsRCR 2.3
- 50 citationsRCR 2.7
- The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.Clin Endocrinol (Oxf) · 201046 citationsRCR 1.4
- High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.Horm Metab Res · 201246 citationsRCR 1.7
- Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.J Clin Endocrinol Metab · 201344 citationsRCR 1.3